Indicators on Eprenetapopt You Should Know
Since authorized in 2014, tucidinostat was considered as a next-line and subsequent therapy for PTCL individuals in China. Clinical trials and preclinical scientific tests in numerous hematological malignancies and reliable tumors is in development.In summary, although the clinical effect of tucidinostat with the treatment of PTCL has been elucidat